SEP 23, 2020 8:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar

CAR T-Cell Immunotherapy of Solid Tumors - Learning from the Clinic and Lab in Parallel

Speakers
  • Clinical Immunologist, Scientific Founder and Chief Scientific Officer of Leucid Bio.
    Biography
      Dr. John Maher is a clinical immunologist who leads the "CAR Mechanics" research group within King's College London. He played a key role in the early development of second generation (CD28) CAR technology while a visiting fellow at Memorial Sloan Kettering Cancer Center, an approach that has achieved clinical impact in haematological malignancies. His research group is focused on the development of adoptive immunotherapy using CAR engineered and gamma delta T-cells, with a primary emphasis on solid tumour types. He is also the scientific founder and chief scientific officer of a spin-out company named Leucid Bio. In addition, he is a consultant immunologist within King's Health Partners and Eastbourne Hospital.
    • Principal Scientist at LUMICKS
      Biography
        Dr. Rogier Reijmers performed his PhD in the lab of Professor Steven Pals where he specialized in B cell development and malignancies. After acquiring his PhD, he continued his academic career in the lab of Dr. Tom Cupedo where he worked on lymph node function and how B cell follicles form. During this period he successfully obtained a highly prestigious VENI scholarship of the Netherlands Organization for Scientific Research, which he used to further study lymph node function in the control of innate lymphoid cell and T cell function. He performed this work in the lab of Professor Reina Mebius. During this period he extended his knowledge on how the lymph node micorenvironment supports B cell malignancies, and was awarded a scholarship from Cancer Center Amsterdam. At the end of his Academic career, he switched places one more time, and started working with Dr. Mirjam Heemskerk, a leading experts in the identification, characterization and subsequent engineering of human T cell receptors. Dr. Reijmers was responsible for all the preclinical work using the identified TCRs. During his academic career, he published nearly 30 papers in many prestigious journals including Blood, the Journal of Clinical Investigation, and Nature Communications. Currently as an expert in Immunology and Hematology, Dr. Reijmers is the Principal Scientist at LUMICKS where he acts as advisor for product strategy and monitors the scientific integrity for immune oncology.

      Abstract
      Date: September 23, 2020
      Time: 8:00am (PDT), 11:00am (EDT)
       
      Over the last couple of years, it has become apparent that affinity-tuned CAR T cells display enhanced expansion and prolonged persistence in patients and that this strategy can result in increased clinical success.
       
      Although affinity screening and measurements for binding kinetics will lead to the identification of a range of affinity-tuned CARs, they will not assist in choosing the optimal candidate. For this reason, a series of standard in vitro assays need to be performed that often requires long-term co-cultures or the use of radioactive isotopes. Besides these drawbacks, such assays do not always accurately predict the most potent candidate(s) for further development for clinical use. In this webinar, we demonstrate that measuring cellular avidity, i.e., overall binding strength between effector and target cell, using z-Movi® Cell Avidity Analyzer, could aid in quickly identifying optimal functioning CARs.
       
      In the first part of the webinar, Dr. Reijmers, Principal Scientist at LUMICKS, will introduce the z-Movi: a novel and unique instrument for accurate and direct measurement of cell–cell interaction strength using acoustic forces. This new technology provides you with predictive, reproducible, and fast high-throughput results at a single-cell level. He will deep-dive into the principle of the z-Movi and will indicate how the workflow enables the determination of precise cell avidity measurements from hundreds of cells simultaneously.
       
      In the second part of the webinar Dr. Maher, CSO at Leucid Bio and group leader of the “CAR Mechanics” research group within King’s College London, will focus on a clinical trial of CAR-T immunotherapy in patients with head and neck cancer using a panErbB-targeted second generation CAR known as T4 immunotherapy. An update on this trial will be provided. He will also describe his efforts to develop a next generation CAR platform known as a parallel (p)CAR in which optimized co-stimulation is delivered by a paired second generation CAR and chimeric co-stimulatory receptor. He will explain how they selected targeting moieties for this approach using the LUMICKS z-Movi technology in order to address the importance of relative binding affinity in the design of optimized pCAR. He will also provide a range of exemplifications of this technology involving distinct targets, binding modules, co-stimulatory modules, and tumor models.
       
       
      Learning objectives:
      • How z-Movi measures cellular avidity.
      • Why avidity matters in CAR-dependent T-cell cytotoxicity.
      • Leucid’s bio’s efforts in developing a next generation CAR platform, known as parallel (p)CAR.
      • How Dr. John Maher uses the z-Movi to address the importance of relative binding affinity in the design of optimized pCAR
       
      Webinars will be available for unlimited on-demand viewing after live event.
       
      LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

      Show Resources
      You May Also Like
      SEP 10, 2020 9:00 AM PDT
      C.E. CREDITS
      SEP 10, 2020 9:00 AM PDT
      Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
      APR 07, 2020 8:00 AM PDT
      C.E. CREDITS
      APR 07, 2020 8:00 AM PDT
      DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
      MAY 08, 2020 10:00 AM PDT
      C.E. CREDITS
      MAY 08, 2020 10:00 AM PDT
      DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
      NOV 10, 2020 7:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      NOV 10, 2020 7:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      DATE: November 10, 2020 TIME: 7:00am PDT, 10:00am EDT Automation can provide tremendous benefits such as increased pipetting precision and accuracy, productivity, and throughput. Numerous wo...
      JUN 23, 2020 10:00 AM PDT
      C.E. CREDITS
      JUN 23, 2020 10:00 AM PDT
      DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
      AUG 18, 2020 10:00 AM PDT
      C.E. CREDITS
      AUG 18, 2020 10:00 AM PDT
      DATE: August 18, 2020 TIME: 10:00am PT Get deeper understanding of gene expression patterns by using assays that retain spatial organization at single cell resolution! Come learn about the n...
      Loading Comments...
      Show Resources
      Event Countdown
      • 0 Days
      • 0 Hours
      • 0 Minutes
      • 0 Seconds
      Attendees
      • See more